Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 9/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.45 |
| ▸ | PKLR | P30613 | 7/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426958 | 0.78 | KAT6A (0.47) | GAAALDH1A1KAT6A | |
| SCHEMBL8224040 | 0.74 | CA1 (0.54) | PKMSLC40A1PKLR | |
| SCHEMBL15116336 | 0.74 | PKM (0.49) | PKMSLC40A1PKLRBRD4GAA | |
| SCHEMBL420075 | 0.74 | PKM (0.49) | PKMSLC40A1PKLRPTGES2BRD4 | |
| SCHEMBL7595736 | 0.71 | SLC40A1 (0.61) | PKMSLC40A1PTGES2BRD4 | |
| SCHEMBL424801 | 0.71 | PKM (0.46) | PKMSLC40A1PKLRPTGES2BRD4 | |
| SCHEMBL427702 | 0.71 | PGR (0.51) | GAAALDH1A1KAT6A | |
| SCHEMBL96565 | 0.69 | PKM (0.66) | PKMSLC40A1PKLRBRD4GAA | |
| SCHEMBL9863745 | 0.69 | PKM (0.43) | PKMSLC40A1PKLRALDH1A1 | |
| SCHEMBL24429357 | 0.69 | MAPT (0.50) | PKMSLC40A1PKLRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2412708-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | ENDOD1, CNBP, DPP4 | PKM 2769/4885SLC40A1 3133/4885PKLR 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.